Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Nature Genetics (2023)
30
Metrics details
The paradigm of cancer-targeted therapies has focused largely on inhibition of critical pathways in cancer. Conversely, conditional activation of signaling pathways as a new source of selective cancer vulnerabilities has not been deeply characterized. In this study, we sought to systematically identify context-specific gene-activation-induced lethalities in cancer. To this end, we developed a method for gain-of-function genetic perturbations simultaneously across ~500 barcoded cancer cell lines. Using this approach, we queried the pan-cancer vulnerability landscape upon activating ten key pathway nodes, revealing selective activation dependencies of MAPK and PI3K pathways associated with specific biomarkers. Notably, we discovered new pathway hyperactivation dependencies in subsets of APC-mutant colorectal cancers where further activation of the WNT pathway by APC knockdown or direct β-catenin overexpression led to robust antitumor effects in xenograft and patient-derived organoid models. Together, this study reveals a new class of conditional gene-activation dependencies in cancer.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Datasets for mutual exclusivity analysis: pan-can TCGA (MC3 Public version, accessed from UCSC Xena), AACR-GENIE (DFCI and MSKCC cohorts, Public v.7.0, accessed from https://www.synapse.org/#!Synapse:syn7222066/wiki/410924), Foundation One (accessed from https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/foundation-medicine) and COSMIC (https://cancer.sanger.ac.uk/cosmic/file_download_info?data=GRCh38%2Fcosmic%2Fv89%2FCosmicMutantExportCensus.tsv.gz). Please note that accessing Foundation Medicine data requires an application to dbGaP for access to the Foundation Medicine Adult Cancer Clinical Dataset (FM-AD) (study accession phs001179). Processed mutual exclusivity analysis is provided in Supplementary Table. PRISM screen data has been uploaded to GEO (raw sequencing data, GSE238126) and provided as Supplementary Table 2 (processed data). RNA-seq analysis has been uploaded to GEO (GSE232944). All genomic data from CCLE is available at https://portals.broadinstitute.org/ccle/data. DepMap 20Q4 was used for all analyses except for mutation analyses (DepMap 22Q1), Extended Data Fig. 2 (DepMap 23Q2) and Extended Data Fig. 3 (Sanger Project Score and GDSC1). Source data are provided with this paper.
All computational analyses were performed in R (v.3.5.2). Source codes are available at https://github.com/sellerslab/SystematicPathwayActivationInCancer.
Chang, L., Ruiz, P., Ito, T. & Sellers, W. R. Targeting pan-essential genes in cancer: challenges and opportunities. Cancer Cell 39, 466–479 (2021).
Article CAS PubMed PubMed Central Google Scholar
Mauro, M. J. & Druker, B. J. STI571: targeting BCR-ABL as therapy for CML. Oncologist 6, 233–238 (2001).
Article CAS PubMed Google Scholar
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science 304, 1497–1500 (2004).
Article CAS PubMed Google Scholar
Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694–1703 (2012).
Article CAS PubMed PubMed Central Google Scholar
Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019).
Article CAS PubMed Google Scholar
Mavrakis, K. J. et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351, 1208–1213 (2016).
Article CAS PubMed Google Scholar
Chan, E. M. et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568, 551–556 (2019).
Article CAS PubMed PubMed Central Google Scholar
Neggers, J. E. et al. Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in cancers harboring loss of chromosome 18q or 16q. Cell Rep. 33, 108493 (2020).
Article CAS PubMed PubMed Central Google Scholar
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293–301 (2010).
Article CAS PubMed PubMed Central Google Scholar
Unni, A. M., Lockwood, W. W., Zejnullahu, K., Lee-Lin, S. Q. & Varmus, H. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. eLife 4, e06907 (2015).
Article PubMed PubMed Central Google Scholar
Ito, T. et al. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nat. Genet. 53, 1664–1672 (2021).
Article CAS PubMed Google Scholar
Leung, G. P. et al. Hyperactivation of MAPK signaling is deleterious to RAS/RAF-mutant melanoma. Mol. Cancer Res. 17, 199–211 (2019).
Article CAS PubMed Google Scholar
Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251–255 (2013).
Article PubMed PubMed Central Google Scholar
Seong, B. K. A. et al. TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma. Cancer Cell 39, 1262–1278.e7 (2021).
Article CAS PubMed PubMed Central Google Scholar
Gallo, D. et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature 604, 749–756 (2022).
Article CAS PubMed PubMed Central Google Scholar
The AACR Project GENIE Consortium. et al. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017).
Article PubMed Central Google Scholar
Sanchez-Vega, F. et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173, 321–337.e10 (2018).
Article CAS PubMed PubMed Central Google Scholar
Hartmaier, R. J. et al. High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis. Cancer Res. 77, 2464–2475 (2017).
Article CAS PubMed Google Scholar
Mina, M. et al. Conditional selection of genomic alterations dictates cancer evolution and oncogenic dependencies. Cancer Cell 32, 155–168.e6 (2017).
Article CAS PubMed Google Scholar
Yu, C. et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat. Biotechnol. 34, 419–423 (2016).
Article CAS PubMed PubMed Central Google Scholar
Corsello, S. M. et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med. 23, 405–408 (2017).
Article CAS PubMed PubMed Central Google Scholar
Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576.e16 (2017).
Article CAS PubMed PubMed Central Google Scholar
Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151–1161 (2013).
Article CAS PubMed PubMed Central Google Scholar
Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503–508 (2019).
Article CAS PubMed PubMed Central Google Scholar
Duffy, M. J., Tang, M., Rajaram, S., O’Grady, S. & Crown, J. Targeting mutant p53 for cancer treatment: moving closer to clinical use? Cancers 14, 4499 (2022).
Article CAS PubMed PubMed Central Google Scholar
Chen, Y.-N. P. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535, 148–152 (2016).
Article CAS PubMed Google Scholar
Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668–682 (2012).
Article CAS PubMed PubMed Central Google Scholar
Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955–D961 (2013).
Article CAS PubMed Google Scholar
Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature 568, 511–516 (2019).
Article CAS PubMed Google Scholar
Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518, 240–244 (2015).
Article CAS PubMed Google Scholar
Oda, K., Stokoe, D., Taketani, Y. & McCormick, F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65, 10669–10673 (2005).
Article CAS PubMed Google Scholar
Matulonis, U. et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol. Oncol. 136, 246–253 (2015).
Article CAS PubMed Google Scholar
Myers, A. P. et al. Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). J. Clin. Oncol. 31, 5524–5524 (2013).
Article Google Scholar
Yaeger, R. et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33, 125–136.e3 (2018).
Article CAS PubMed PubMed Central Google Scholar
Lepourcelet, M. et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5, 91–102 (2004).
Article CAS PubMed Google Scholar
Liao, H. et al. A PROTAC peptide induces durable β-catenin degradation and suppresses Wnt-dependent intestinal cancer. Cell Discov. 6, 35 (2020).
Article CAS PubMed PubMed Central Google Scholar
Grossmann, T. N. et al. Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin. Proc. Natl Acad. Sci. USA 109, 17942–17947 (2012).
Article CAS PubMed PubMed Central Google Scholar
Levine, A. J., Jenkins, N. A. & Copeland, N. G. The roles of initiating truncal mutations in human cancers: the order of mutations and tumor cell type matters. Cancer Cell 35, 10–15 (2019).
Article CAS PubMed PubMed Central Google Scholar
Christie, M. et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene 32, 4675–4682 (2013).
Article CAS PubMed Google Scholar
Albuquerque, C. et al. The ‘just-right’ signaling model: APC somatic mutations are selected based on a specific level of activation of the β-catenin signaling cascade. Hum. Mol. Genet. 11, 1549–1560 (2002).
Article CAS PubMed Google Scholar
Ranes, M., Zaleska, M., Sakalas, S., Knight, R. & Guettler, S. Reconstitution of the destruction complex defines roles of AXIN polymers and APC in β-catenin capture, phosphorylation, and ubiquitylation. Mol. Cell 81, 3246–3261.e11 (2021).
Article CAS PubMed PubMed Central Google Scholar
Schneikert, J., Grohmann, A. & Behrens, J. Truncated APC regulates the transcriptional activity of β-catenin in a cell cycle dependent manner. Hum. Mol. Genet. 16, 199–209 (2007).
Article CAS PubMed Google Scholar
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
Article Google Scholar
Golshani, G. & Zhang, Y. Advances in immunotherapy for colorectal cancer: a review. Ther. Adv. Gastroenterol. 13, 1756284820917527 (2020).
Article CAS Google Scholar
Nusse, R. & Clevers, H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999 (2017).
Article CAS PubMed Google Scholar
Krishnamurthy, N. & Kurzrock, R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat. Rev. 62, 50–60 (2018).
Article CAS PubMed Google Scholar
Jung, Y.-S. & Park, J.-I. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp. Mol. Med. 52, 183–191 (2020).
Article CAS PubMed PubMed Central Google Scholar
Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118–122 (2014).
Article CAS PubMed Google Scholar
Unni, A. M. et al. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. eLife 7, e33718 (2018).
Article PubMed PubMed Central Google Scholar
Saghafinia, S. et al. Conditional selection of genomic alterations dictates cancer evolution and oncogenic dependencies. Cancer Cell 32, 155–168.e6 (2017).
Article PubMed Google Scholar
Soumerai, T. E. et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin. Cancer Res. 24, 5939–5947 (2018).
Article CAS PubMed PubMed Central Google Scholar
Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385.e18 (2018).
Article CAS PubMed PubMed Central Google Scholar
Dou, Y. et al. Proteogenomic characterization of endometrial carcinoma. Cell 180, 729–748.e26 (2020).
Article CAS PubMed PubMed Central Google Scholar
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
Article PubMed Google Scholar
Sweeney, S. M. et al. AACR project genie: powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017).
Article Google Scholar
Corsello, S. M. et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235–248 (2020).
Article CAS PubMed PubMed Central Google Scholar
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Article CAS PubMed Google Scholar
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
Article PubMed PubMed Central Google Scholar
Cornwell, M. et al. VIPER: visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. BMC Bioinf. 19, 135 (2018).
Article Google Scholar
Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011).
Article CAS PubMed Google Scholar
Download references
We thank K. Polyak, S. Elledge, M. Meyerson and the members of the Sellers laboratory for helpful discussions. We thank Broad Institute Genomics Platform, Broad Institute PRISM Laboratory, Broad Institute Comparative Medicine and DFCI Molecular Biology Core Facilities for their technical support.
Broad Institute of MIT and Harvard, Cambridge, MA, USA
Liang Chang, Nancy Y. Jung, Adel Atari, Diego J. Rodriguez, Devishi Kesar, Tian-Yu Song, Matthew G. Rees, Melissa Ronan, Ruitong Li, Paloma Ruiz, Saireudee Chaturantabut, Takahiro Ito, Laurens M. van Tienen, Yuen-Yi Tseng, Jennifer A. Roth & William R. Sellers
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Liang Chang, Tian-Yu Song, Saireudee Chaturantabut, Laurens M. van Tienen & William R. Sellers
Harvard Medical School, Boston, MA, USA
Liang Chang, Tian-Yu Song, Saireudee Chaturantabut, Laurens M. van Tienen & William R. Sellers
Department of Biopharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand
Saireudee Chaturantabut
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
L.C. and W.R.S. conceived the studies. L.C., M.G.R., M.R. and J.A.R. designed and executed the PRISM GOF screen. L.C., D.K. and R.L. performed bioinformatic and statistical analysis. L.C., N.Y.J. and P.R. performed in vitro validation experiments and analysis. D.J.R., L.C., N.Y.J., S.C. and T.-Y.S. performed mouse xenograft experiments. A.A. and Y.-Y.T. performed patient-derived organoid validation experiments. T.I. and L.M.v.T. provided critical insights into experimental design and interpretation. L.C. and W.R.S. wrote the paper, with critical reading and feedback from other coauthors.
Correspondence to William R. Sellers.
W.R.S. is a Board or SAB member and holds equity in Ideaya Biosciences, Civetta Therapeutics, Red Ridge Bio, Delphia Therapeutics, Scorpion Therapeutics and 2Seventy Bio. Delphia Therapeutics is exploring GOF therapeutics in cancer. W.R.S. has consulted for Array, Astex, Epidarex Capital, Ipsen, PearlRiver Therapeutics, Merck Pharmaceuticals, Sanofi, Servier and Syndax Pharmaceuticals and receives research funding from Pfizer Pharmaceuticals, Merck Pharmaceuticals, Ideaya Biosciences, Calico, Boehringer-Ingelheim, Bristol Myers Squibb, Bayer Pharmaceuticals, Novartis Institutes for Biomedical Research and Ridgeline Discovery. W.R.S. is a copatent holder on EGFR mutation diagnostic patents. L.C. is an employee of Cure Ventures and was a previous employee of 5AM Ventures and Flagship Pioneering. T.I. is an equity holder of Scorpion Therapeutics and Odyssey Therapeutics. All other authors declare no competing interests.
Nature Genetics thanks Kris Wood and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Correlation of cell line barcode reads between barcode PCR technical replicates (n = 2) across all ORF conditions (n = 11). Y-axis represents the Pearson correlation coefficients, and each bar represents a biological condition.
The Y-axis represents the Chronos score of gene CRISPR knockout dependencies in each cell line. The X-axis represents the log-fold change (LogFC) of each cell line resulting from ORF overexpression compared to GFP overexpression. a, Relationship between the viability effects of p53 ORF overexpression (X-axis) and the viability effects of TP53 knockout (Y-axis) in 488 cancer cell lines. Each dot represents a cancer cell line colored by TP53 hotspot mutation status as indicated. b, Relationship between the viability effects of p16 ORF overexpression (X-axis) and the viability effects of CDK6 knockout (Y-axis) in 488 cancer cell lines. Each dot represents a cancer cell line colored by RB1 hotspot mutation status as indicated. c, Relationship between the viability effects of PTEN ORF overexpression (X-axis) and the viability effects of PIK3CA knockout (Y-axis) in 488 cancer cell lines. Each dot represents a cancer cell line colored by PIK3CA hotspot mutation status as indicated.
Box plot showing differential ERK2 overexpression according to BRAF or NRAS hotspot/recurrence mutation status in 488 cell lines. The Y-axis represents the log-fold change (LogFC) of each cell line upon ERK2 overexpression compared with GFP overexpression. P-values by unpaired two-sided t-test. The box in this figure shows the median (the middle line) and the 25–75th percentiles (the box); the whiskers show 1.5× the interquartile range from the lower and upper quartile.
a, b, Genetic and drug perturbation features associated with differential viability effects resulting from p53 overexpression. (a) Pairwise correlation of the viability effects of p53 overexpression with ~20,000 CRISPR dependency features (Project Score) in 152 overlapping cell lines. The Y-axis represents the statistical significance (-log10_pvalue) of each pair of associations from the Pearson correlation analysis, and the X-axis represents the Pearson correlation coefficient for each association pair. (b) Correlation between ~300 compound sensitivity (Sanger GDSC1 dataset) features and p53 overexpression viability effects across ~300 cell lines. Axes are as shown in a. c, d, Genetic and drug perturbation features associated with differential viability effects resulting from p16 overexpression. (c) Pairwise correlation of the viability effects of p16 overexpression with ~20,000 CRISPR dependency features (Project Score) in 152 cell lines. The Y-axis represents the statistical significance (-log10_pvalue) of each pair of associations from the Pearson correlation analysis, and the X-axis represents the Pearson correlation coefficient for each association pair. (d) Correlation between ~300 compound sensitivity (Sanger GDSC1 dataset) features and p16 overexpression viability effects across ~300 cell lines. Axes are as shown in a. e, f, Genetic and drug perturbation features associated with differential viability effects resulting from (e) PTEN and (f) overexpression. Pairwise correlation between ~300 compound sensitivity (Sanger GDSC1 dataset) features and PTEN overexpression viability effects across ~300 cell lines. The Y-axis represents the statistical significance (-log10_pvalue) of each pair of associations from the Pearson correlation analysis, and the X-axis represents the Pearson correlation coefficient for each association pair. Colors of points represent positive (brown) and negative (purple) Pearson correlation coefficients. ‘Inhibitor’ is denoted by ‘i’ in point labels.
Immunoblot of indicated proteins from extracts prepared from the indicated cell lines ectopically expressing GFP, AKT1E17K and AKT1E17K,K179A (all with V5 tag). Each experiment was repeated independently two times. Row gel scanning images are provided in Source Data Extended Data Fig. 1.
Source data
a, Quantitative RT-qPCR of indicated mRNAs in cells after transduction of non-targeting shRNA (NT1) and anti-APC shRNAs (APC-shRNA#1 and #3). The Y-axis represents the expression level of each indicated gene relative to NT1 control. Bars represent means and the error bars represent standard deviations in each group across n = 3 biologically independent samples. b, Quantitative RT-qPCR of indicated mRNAs in cells after transduction of non-targeting shRNA (NT1) and anti-CSNK1A1 shRNA in HT29 (left) and RKO (right) cells. The Y-axis represents the expression level of each indicated gene relative to NT1 control. Bars represent means and the error bars represent standard deviations in each group across n = 3 biologically independent samples.
a, b, Volcano plots showing the top significantly up- and down-regulated genes detected by RNAseq comparing (a) APC-shRNA-transduced and NT-shRNA-transduced and (b) GFP-transduced to β-catenin-transduced HT29 cells. The Y-axis represents the statistical significance (-log10_pvalue) of each gene, and the X-axis represents the log2 (fold change) for each gene. Selective genes related to the WNT or cell cycle pathways are labeled. Colors of dots are annotated as: gene with statistically significant positive log2 fold change (red), negative fold change (grey), or no significant change (black). Dotted line represents the statistical significance cutoff of p = 0.01. c, Gene-Set Enrichment Analysis (GSEA) showing selective significantly enriched and depleted pathways related to cell cycle and WNT signaling in GFP compared to β-catenin transduced HT29 cells. The X-axis represents the Normalized Enrichment Score of each gene module. The adjusted p value for each gene module is indicated.
a, b, FACS-based detection of Annexin V-FITC stained RKO and HT29 cells indicating apoptotic cells, (a) 5 days after β-catenin or β-catenin-D164AΔC (non-TCF-binding negative control) overexpression, and (b) 4 days after APC shRNA or non-targeting shRNA infection (including 2 days of doxycycline induction). The percentage of Annexin V-FITC positive cells relative to total analyzed cells in each replicate is indicated. c, d, FACS-based detection of β-Gal-stained RKO and HT29 cells indicating senescent cells, (c) 5 days after β-catenin or β-catenin-D163AΔC (non-TCF-binding negative control) overexpression, or (d) 2 days after APC shRNA or non-targeting shRNA induction (including 2 days of doxycycline induction). Empty circles indicate no addition of β-Gal staining substrate, and solid circle indicate addition of β-Gal staining substrate. e-f, FACS gating strategies for (e) Annexin V-FITC staining in a-b, and (f) β-Gal staining in c-d.
a, APC mutation status of 3 patient-derived organoids. b, representative pictures of 3 patient-derived organoids after transduction of a lentivirus encoding GFP. Experiment was performed once because of the assay development nature.
In cancer models with specific driver mutations that activate certain oncogenic pathways (MAPK, PI3K, WNT), the elevations of background signaling make them susceptible to loss of viability mediated by further activations of the initially altered signaling pathway.
Mutual exclusivity analysis of genome mutations in 69,393 patients with cancer using the SELECT algorithm; logFC scores of the ORF overexpression screen (normalized to GFP).
Unprocessed western blots.
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and Permissions
Chang, L., Jung, N.Y., Atari, A. et al. Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nat Genet (2023). https://doi.org/10.1038/s41588-023-01515-7
Download citation
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41588-023-01515-7
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
Advertisement
© 2023 Springer Nature Limited
Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.